Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Heather Jane Ribaudo, Ph.D.

Title
Institution
Department
Address
Phone

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Hsue PY, Ribaudo HJ, Deeks SG, Bell T, Ridker PM, Fichtenbaum C, Daar ES, Havlir D, Yeh E, Tawakol A, Lederman M, Currier JS, Stein JH. Safety and Impact of Low-dose Methotrexate on Endothelial Function and Inflammation in Individuals With Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314. Clin Infect Dis. 2019 May 17; 68(11):1877-1886. PMID: 30219823.
    Citations:    Fields:    
  2. Yin MT, Chan ES, Brown TT, Kinslow J, Martinson J, Landay A, Melbourne KM, Ribaudo HJ, Overton ET. Vitamin D does not modulate immune-mediated bone loss during ART initiation. Antivir Ther. 2019 May 14. PMID: 31085814.
    Citations:    
  3. Abulizi X, Ribaudo HJ, Flandre P. The Use of the Restricted Mean Survival Time as a Treatment Measure in HIV/AIDS Clinical Trial: Reanalysis of the ACTG A5257 Trial. J Acquir Immune Defic Syndr. 2019 May 01; 81(1):44-51. PMID: 30789450.
    Citations:    
  4. Gandhi M, Bacchetti P, Ofokotun I, Jin C, Ribaudo HJ, Haas DW, Sheth AN, Horng H, Phung N, Kuncze K, Okochi H, Landovitz RJ, Lennox J, Currier JS. Antiretroviral Concentrations in Hair Strongly Predict Virologic Response in a Large Human Immunodeficiency Virus Treatment-naive Clinical Trial. Clin Infect Dis. 2019 Mar 05; 68(6):1044-1047. PMID: 30184104.
    Citations:    Fields:    
  5. Hoffmann U, Lu MT, Olalere D, Adami EC, Osborne MT, Ivanov A, Aluru JS, Lee S, Arifovic N, Overton ET, Fichtenbaum CJ, Aberg JA, Alston-Smith B, Klingman KL, Waclawiw M, Burdo TH, Williams KC, Zanni MV, Desvigne-Nickens P, Cooper-Arnold K, Fitch KV, Ribaudo H, Douglas PS, Grinspoon SK. Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers. Am Heart J. 2019 Mar 04; 212:1-12. PMID: 30928823.
    Citations:    
  6. Grinspoon SK, Fitch KV, Overton ET, Fichtenbaum CJ, Zanni MV, Aberg JA, Malvestutto C, Lu MT, Currier JS, Sponseller CA, Waclawiw M, Alston-Smith B, Cooper-Arnold K, Klingman KL, Desvigne-Nickens P, Hoffmann U, Ribaudo HJ, Douglas PS. Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). Am Heart J. 2019 Mar 04; 212:23-35. PMID: 30928825.
    Citations:    
  7. Bhagwat P, Kapadia SN, Ribaudo HJ, Gulick RM, Currier JS. Racial Disparities in Virologic Failure and Tolerability During Firstline HIV Antiretroviral Therapy. Open Forum Infect Dis. 2019 Feb; 6(2):ofz022. PMID: 30793009.
    Citations:    
  8. Dubé MP, Chan ES, Lake JE, Williams B, Kinslow J, Landay A, Coombs RW, Floris-Moore M, Ribaudo HJ, Yarasheski KE. A Randomized, Double-Blinded, Placebo-Controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed HIV Infection. Clin Infect Dis. 2018 Dec 10. PMID: 30535188.
    Citations:    Fields:    
  9. Stein JH, Yeh E, Weber JM, Korcarz C, Ridker PM, Tawakol A, Hsue PY, Currier JS, Ribaudo H, Mitchell CKC. Brachial Artery Echogenicity and Grayscale Texture Changes in HIV-Infected Individuals Receiving Low-Dose Methotrexate. Arterioscler Thromb Vasc Biol. 2018 Dec; 38(12):2870-2878. PMID: 30571173.
    Citations:    Fields:    
  10. Muhammad J, Chan ES, Brown TT, Tebas P, McComsey GA, Melbourne K, Hardin R, Willig AL, Yin MT, Ribaudo H, Overton ET. Vitamin D Supplementation Does Not Affect Metabolic Changes Seen With ART Initiation. Open Forum Infect Dis. 2017; 4(4):ofx210. PMID: 29255724.
    Citations:    
  11. Yin MT, Chan ES, Brown TT, Tebas P, McComsey GA, Melbourne KM, Napoli A, Hardin WR, Ribaudo HJ, Overton ET. Racial differences in calculated bioavailable vitamin D with vitamin D/calcium supplementation. AIDS. 2017 11 13; 31(17):2337-2344. PMID: 28832406.
    Citations:    Fields:    Translation:Humans
  12. Landovitz RJ, Tran TT, Cohn SE, Ofotokun I, Godfrey C, Kuritzkes DR, Lennox JL, Currier JS, Ribaudo HJ. HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States. AIDS Behav. 2016 12; 20(12):2983-2995. PMID: 26979419.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  13. Matoga MM, Hosseinipour MC, Aga E, Ribaudo HJ, Kumarasamy N, Bartlett J, Hughes MD. Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings. Antivir Ther. 2017; 22(3):205-213. PMID: 27740537.
    Citations: 2     Fields:    Translation:Humans
  14. Kelesidis T, Tran TTT, Brown TT, Moser C, Ribaudo HJ, Dube MP, Yang OO, McComsey GA, Stein JH, Currier JS. Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s. Antivir Ther. 2017; 22(2):113-126. PMID: 27661466.
    Citations: 2     Fields:    
  15. Chan ES, Landay AL, Brown TT, Ribaudo HJ, Mirmonsef P, Ofotokun I, Weitzmann MN, Martinson J, Klingman KL, Eron JJ, Fichtenbaum CJ, Plants J, Taiwo BO. Differential CD4+ cell count increase and CD4+?: ?CD8+ ratio normalization with maraviroc compared with tenofovir. AIDS. 2016 08 24; 30(13):2091-7. PMID: 27281061.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  16. Zash R, Souda S, Leidner J, Ribaudo H, Binda K, Moyo S, Powis KM, Petlo C, Mmalane M, Makhema J, Essex M, Lockman S, Shapiro R. HIV-exposed children account for more than half of 24-month mortality in Botswana. BMC Pediatr. 2016 07 21; 16:103. PMID: 27439303.
    Citations: 5     Fields:    Translation:Humans
  17. Kelesidis T, Moser C, Stein JH, Brown TT, Tran TT, Ribaudo HJ, Dube MP, Yang OO, Currier JS, McComsey GA. Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. J Infect Dis. 2016 09 01; 214(5):748-52. PMID: 27354367.
    Citations:    Fields:    Translation:HumansCells
  18. McComsey GA, Moser C, Currier J, Ribaudo HJ, Paczuski P, Dubé MP, Kelesidis T, Rothenberg J, Stein JH, Brown TT. Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s. Clin Infect Dis. 2016 Apr 01; 62(7):853-62. PMID: 26797215.
    Citations: 25     Fields:    Translation:Humans
  19. Cillo AR, Hilldorfer BB, Lalama CM, McKinnon JE, Coombs RW, Tenorio AR, Fox L, Gandhi RT, Ribaudo H, Currier JS, Gulick RM, Wilkin TJ, Mellors JW. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery. AIDS. 2015 Oct 23; 29(16):2121-9. PMID: 26544577.
    Citations: 8     Fields:    Translation:HumansCellsCTClinical Trials
  20. Stein JH, Ribaudo HJ, Hodis HN, Brown TT, Tran TT, Yan M, Brodell EL, Kelesidis T, McComsey GA, Dube MP, Murphy RL, Currier JS. A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness. AIDS. 2015 Sep 10; 29(14):1775-83. PMID: 26372383.
    Citations: 19     Fields:    Translation:HumansCellsCTClinical Trials
  21. Vardhanabhuti S, Ribaudo HJ, Landovitz RJ, Ofotokun I, Lennox JL, Currier JS, Olson LM, Haas DW. Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia. Open Forum Infect Dis. 2015 Sep; 2(3):ofv085. PMID: 26180834.
    Citations: 10     
  22. Overton ET, Chan ES, Brown TT, Tebas P, McComsey GA, Melbourne KM, Napoli A, Hardin WR, Ribaudo HJ, Yin MT. Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial. Ann Intern Med. 2015 Jun 16; 162(12):815-24. PMID: 26075752.
    Citations: 21     Fields:    Translation:HumansCells
  23. Lalama CM, Jennings C, Johnson VA, Coombs RW, McKinnon JE, Bremer JW, Cobb BR, Cloherty GA, Mellors JW, Ribaudo HJ. Comparison of Three Different FDA-Approved Plasma HIV-1 RNA Assay Platforms Confirms the Virologic Failure Endpoint of 200 Copies per Milliliter Despite Improved Assay Sensitivity. J Clin Microbiol. 2015 Aug; 53(8):2659-66. PMID: 26063861.
    Citations:    Fields:    Translation:HumansCells
  24. Taiwo BO, Chan ES, Fichtenbaum CJ, Ribaudo H, Tsibris A, Klingman KL, Eron JJ, Berzins B, Robertson K, Landay A, Ofotokun I, Brown T. Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study. Clin Infect Dis. 2015 Oct 01; 61(7):1179-88. PMID: 26060295.
    Citations: 16     Fields:    Translation:Humans
  25. Brown TT, Moser C, Currier JS, Ribaudo HJ, Rothenberg J, Kelesidis T, Yang O, Dubé MP, Murphy RL, Stein JH, McComsey GA. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir. J Infect Dis. 2015 Oct 15; 212(8):1241-9. PMID: 25948863.
    Citations: 23     Fields:    Translation:HumansCells
  26. Kelesidis T, Tran TT, Stein JH, Brown TT, Moser C, Ribaudo HJ, Dube MP, Murphy R, Yang OO, Currier JS, McComsey GA. Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. Clin Infect Dis. 2015 Aug 15; 61(4):651-60. PMID: 25904376.
    Citations: 26     Fields:    Translation:Humans
  27. Lennox JL, Landovitz RJ, Ribaudo HJ. Three nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1. Ann Intern Med. 2015 Mar 17; 162(6):461-2. PMID: 25775334.
    Citations:    Fields:    Translation:HumansCells
  28. Ofotokun I, Na LH, Landovitz RJ, Ribaudo HJ, McComsey GA, Godfrey C, Aweeka F, Cohn SE, Sagar M, Kuritzkes DR, Brown TT, Patterson KB, Para MF, Leavitt RY, Villasis-Keever A, Baugh BP, Lennox JL, Currier JS. Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. Clin Infect Dis. 2015 06 15; 60(12):1842-51. PMID: 25767256.
    Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
  29. Kumarasamy N, Aga E, Ribaudo HJ, Wallis CL, Katzenstein DA, Stevens WS, Norton MR, Klingman KL, Hosseinipour MC, Crump JA, Supparatpinyo K, Badal-Faesen S, Bartlett JA. Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230. Clin Infect Dis. 2015 May 15; 60(10):1552-8. PMID: 25694653.
    Citations: 4     Fields:    Translation:HumansCells
  30. Lehmann DS, Ribaudo HJ, Daar ES, Gulick RM, Haubrich RH, Robbins GK, de Bakker PI, Haas DW, McLaren PJ. Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenet Genomics. 2015 Feb; 25(2):51-9. PMID: 25461247.
    Citations: 5     Fields:    Translation:HumansCells
  31. Konstantopoulos C, Ribaudo H, Ragland K, Bangsberg DR, Li JZ. Antiretroviral regimen and suboptimal medication adherence are associated with low-level human immunodeficiency virus viremia. Open Forum Infect Dis. 2015 Jan; 2(1):ofu119. PMID: 25884007.
    Citations: 6     
  32. Li JZ, Arnold KB, Lo J, Dugast AS, Plants J, Ribaudo HJ, Cesa K, Heisey A, Kuritzkes DR, Lauffenburger DA, Alter G, Landay A, Grinspoon S, Pereyra F. Differential levels of soluble inflammatory markers by human immunodeficiency virus controller status and demographics. Open Forum Infect Dis. 2015 Jan; 2(1):ofu117. PMID: 25884005.
    Citations: 16     
  33. Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS. Summaries for patients. Nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1. Ann Intern Med. 2014 Oct 07; 161(7):I-22. PMID: 25285557.
    Citations:    Fields:    Translation:HumansCells
  34. Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med. 2014 Oct 07; 161(7):461-71. PMID: 25285539.
    Citations: 51     Fields:    Translation:HumansCellsCTClinical Trials
  35. Zanni MV, Fitch KV, Feldpausch M, Han A, Lee H, Lu MT, Abbara S, Ribaudo H, Douglas PS, Hoffmann U, Lo J, Grinspoon SK. 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque. AIDS. 2014 Sep 10; 28(14):2061-70. PMID: 25265074.
    Citations: 27     Fields:    Translation:Humans
  36. Henrich TJ, McLaren PJ, Rao SS, Lin NH, Hanhauser E, Giguel F, Gulick RM, Ribaudo H, de Bakker PI, Kuritzkes DR. Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study. Open Forum Infect Dis. 2014 Mar; 1(1):ofu018. PMID: 25734091.
    Citations: 2     
  37. Wallis CL, Aga E, Ribaudo H, Saravanan S, Norton M, Stevens W, Kumarasamy N, Bartlett J, Katzenstein D. Drug susceptibility and resistance mutations after first-line failure in resource limited settings. Clin Infect Dis. 2014 Sep 01; 59(5):706-15. PMID: 24795328.
    Citations: 15     Fields:    Translation:HumansCells
  38. Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Eron J, Chen YQ, Wang L, Ou SS, Anderson M, McCauley M, Gamble T, Kumarasamy N, Hakim JG, Kumwenda J, Pilotto JH, Godbole SV, Chariyalertsak S, de Melo MG, Mayer KH, Eshleman SH, Piwowar-Manning E, Makhema J, Mills LA, Panchia R, Sanne I, Gallant J, Hoffman I, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Havlir D, Cohen MS. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014 Apr; 14(4):281-90. PMID: 24602844.
    Citations: 128     Fields:    Translation:HumansCellsCTClinical Trials
  39. Li JZ, Gallien S, Ribaudo H, Heisey A, Bangsberg DR, Kuritzkes DR. Incomplete adherence to antiretroviral therapy is associated with higher levels of residual HIV-1 viremia. AIDS. 2014 Jan 14; 28(2):181-186. PMID: 24361679.
    Citations: 19     Fields:    Translation:HumansCells
  40. Ribaudo HJ, Smith KY, Robbins GK, Flexner C, Haubrich R, Chen Y, Fischl MA, Schackman BR, Riddler SA, Gulick RM. Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis. Clin Infect Dis. 2013 Dec; 57(11):1607-17. PMID: 24046302.
    Citations: 9     Fields:    Translation:Humans
  41. Johnson BA, Ribaudo H, Gulick RM, Eron JJ. Modeling clinical endpoints as a function of time of switch to second-line ART with incomplete data on switching times. Biometrics. 2013 Sep; 69(3):732-40. PMID: 23862631.
    Citations: 2     Fields:    Translation:Humans
  42. Brown TT, Chen Y, Currier JS, Ribaudo HJ, Rothenberg J, Dubé MP, Murphy R, Stein JH, McComsey GA. Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2013 Jul 01; 63(3):323-30. PMID: 23591634.
    Citations: 20     Fields:    Translation:HumansCellsCTClinical Trials
  43. Vardhanabhuti S, Acosta EP, Ribaudo HJ, Severe P, Lalloo U, Kumarasamy N, Taulo F, Kabanda J, Oneko O, Ive P, Sambarey P, Chan ES, Hitti J, Hong F, McMahon D, Haas DW. Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission. J Infect Dis. 2013 Aug 15; 208(4):662-71. PMID: 23687222.
    Citations: 8     Fields:    Translation:Humans
  44. Stein JH, Brown TT, Ribaudo HJ, Chen Y, Yan M, Lauer-Brodell E, McComsey GA, Dubé MP, Murphy RL, Hodis HN, Currier JS. Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection. AIDS. 2013 Mar 27; 27(6):929-37. PMID: 23196938.
    Citations: 26     Fields:    Translation:Humans
  45. Overton ET, Kitch D, Benson CA, Hunt PW, Stein JH, Smurzynski M, Ribaudo HJ, Tebas P. Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death. Clin Infect Dis. 2013 May; 56(10):1471-9. PMID: 23386631.
    Citations: 25     Fields:    Translation:Humans
  46. Schackman BR, Haas DW, Becker JE, Berkowitz BK, Sax PE, Daar ES, Ribaudo HJ, Freedberg KA. Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV disease. Antivir Ther. 2013; 18(3):399-408. PMID: 23264445.
    Citations: 6     Fields:    Translation:Humans
  47. Li JZ, Paredes R, Ribaudo HJ, Kozal MJ, Svarovskaia ES, Johnson JA, Geretti AM, Metzner KJ, Jakobsen MR, Hullsiek KH, Ostergaard L, Miller MD, Kuritzkes DR. Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure. J Infect Dis. 2013 Mar 15; 207(6):893-7. PMID: 23264671.
    Citations: 19     Fields:    Translation:HumansCells
  48. Holzinger ER, Grady B, Ritchie MD, Ribaudo HJ, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford DB, Daar ES, McLaren P, Haas DW. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Pharmacogenet Genomics. 2012 Dec; 22(12):858-67. PMID: 23080225.
    Citations: 44     Fields:    Translation:Humans
  49. Ribaudo HJ, Daar ES, Tierney C, Morse GD, Mollan K, Sax PE, Fischl MA, Collier AC, Haas DW. Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202. J Infect Dis. 2013 Feb 01; 207(3):420-5. PMID: 23148286.
    Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
  50. Chen JY, Ribaudo HJ, Souda S, Parekh N, Ogwu A, Lockman S, Powis K, Dryden-Peterson S, Creek T, Jimbo W, Madidimalo T, Makhema J, Essex M, Shapiro RL. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis. 2012 Dec 01; 206(11):1695-705. PMID: 23066160.
    Citations: 73     Fields:    Translation:Humans
  51. Li L, Eron JJ, Ribaudo H, Gulick RM, Johnson BA. Evaluating the Effect of Early Versus Late ARV Regimen Change if Failure on an Initial Regimen: Results From the AIDS Clinical Trials Group Study A5095. J Am Stat Assoc. 2012; 107(498):542-554. PMID: 23329858.
    Citations: 5     
  52. Bartlett JA, Ribaudo HJ, Wallis CL, Aga E, Katzenstein DA, Stevens WS, Norton MR, Klingman KL, Hosseinipour MC, Crump JA, Supparatpinyo K, Badal-Faesen S, Kallungal BA, Kumarasamy N. Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings. AIDS. 2012 Jul 17; 26(11):1345-54. PMID: 22441252.
    Citations: 14     Fields:    Translation:Humans
  53. Wilkin TJ, Lalama CM, McKinnon J, Gandhi RT, Lin N, Landay A, Ribaudo H, Fox L, Currier JS, Mellors JW, Gulick R, Tenorio AR. A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4? T-cell recovery despite sustained virologic suppression: ACTG A5256. J Infect Dis. 2012 Aug 15; 206(4):534-42. PMID: 22740718.
    Citations: 30     Fields:    Translation:HumansCellsCTClinical Trials
  54. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Kozal MJ, Hullsiek KH, Miller MD, Bangsberg DR, Kuritzkes DR. Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure. AIDS. 2012 Jan 14; 26(2):185-92. PMID: 22179227.
    Citations: 33     Fields:    Translation:HumansCells
  55. Shapiro RL, Ribaudo H, Powis K, Chen J, Parekh N. Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes. AIDS. 2012 Jan 02; 26(1):120-1. PMID: 22126816.
    Citations: 2     Fields:    Translation:HumansCells
  56. Matthews LT, Ribaudo HJ, Parekh NK, Chen JY, Binda K, Ogwu A, Makhema J, Souda S, Lockman S, Essex M, Shapiro RL. Birth weight for gestational age norms for a large cohort of infants born to HIV-negative women in Botswana compared with norms for U.S.-born black infants. BMC Pediatr. 2011 Dec 16; 11:115. PMID: 22176889.
    Citations: 7     Fields:    Translation:HumansCells
  57. Haubrich RH, Riddler SA, Ribaudo H, Direnzo G, Klingman KL, Garren KW, Butcher DL, Rooney JF, Havlir DV, Mellors JW. Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection. AIDS. 2011 Nov 28; 25(18):2269-78. PMID: 21941167.
    Citations: 8     Fields:    Translation:HumansCellsCTClinical Trials
  58. Mugavero MJ, May M, Ribaudo HJ, Gulick RM, Riddler SA, Haubrich R, Napravnik S, Abgrall S, Phillips A, Harris R, Gill MJ, de Wolf F, Hogg R, Günthard HF, Chêne G, D'Arminio Monforte A, Guest JL, Smith C, Murillas J, Berenguer J, Wyen C, Domingo P, Kitahata MM, Sterne JA, Saag MS. Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study. J Acquir Immune Defic Syndr. 2011 Nov 01; 58(3):253-60. PMID: 21857357.
    Citations: 7     Fields:    Translation:HumansCells
  59. Haas DW, Kuritzkes DR, Ritchie MD, Amur S, Gage BF, Maartens G, Masys D, Fellay J, Phillips E, Ribaudo HJ, Freedberg KA, Petropoulos C, Manolio TA, Gulick RM, Haubrich R, Kim P, Dehlinger M, Abebe R, Telenti A. Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases. HIV Clin Trials. 2011 Sep-Oct; 12(5):277-85. PMID: 22180526.
    Citations: 6     Fields:    Translation:HumansCells
  60. Taiwo B, Gallien S, Aga E, Ribaudo H, Haubrich R, Kuritzkes DR, Eron JJ. Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy. J Infect Dis. 2011 Aug 15; 204(4):515-20. PMID: 21791652.
    Citations: 23     Fields:    Translation:HumansCells
  61. Parekh N, Ribaudo H, Souda S, Chen J, Mmalane M, Powis K, Essex M, Makhema J, Shapiro RL. Risk factors for very preterm delivery and delivery of very-small-for-gestational-age infants among HIV-exposed and HIV-unexposed infants in Botswana. Int J Gynaecol Obstet. 2011 Oct; 115(1):20-5. PMID: 21767835.
    Citations: 8     Fields:    Translation:Humans
  62. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Fleming TR. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011 Aug 11; 365(6):493-505. PMID: 21767103.
    Citations: 2149     Fields:    Translation:HumansCells
  63. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, Kozal MJ, Hullsiek KH, Balduin M, Jakobsen MR, Geretti AM, Thiebaut R, Ostergaard L, Masquelier B, Johnson JA, Miller MD, Kuritzkes DR. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA. 2011 Apr 06; 305(13):1327-35. PMID: 21467286.
    Citations: 116     Fields:    Translation:HumansCells
  64. Ribaudo HJ, Benson CA, Zheng Y, Koletar SL, Collier AC, Lok JJ, Smurzynski M, Bosch RJ, Bastow B, Schouten JT. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis. 2011 Apr 01; 52(7):929-40. PMID: 21427402.
    Citations: 43     Fields:    Translation:Humans
  65. Grady BJ, Torstenson ES, McLaren PJ, DE Bakker PI, Haas DW, Robbins GK, Gulick RM, Haubrich R, Ribaudo H, Ritchie MD. Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participants. Pac Symp Biocomput. 2011; 253-64. PMID: 21121053.
    Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
  66. Shikuma CM, Ribaudo HJ, Zheng Y, Gulick RM, Meyer WA, Tashima KT, Bastow B, Kuritzkes DR, Glesby MJ. Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals. AIDS Res Hum Retroviruses. 2011 May; 27(5):461-8. PMID: 20863238.
    Citations: 18     Fields:    Translation:Humans
  67. Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, Ripke S, Brumme CJ, Pulit SL, Carrington M, Kadie CM, Carlson JM, Heckerman D, Graham RR, Plenge RM, Deeks SG, Gianniny L, Crawford G, Sullivan J, Gonzalez E, Davies L, Camargo A, Moore JM, Beattie N, Gupta S, Crenshaw A, Burtt NP, Guiducci C, Gupta N, Gao X, Qi Y, Yuki Y, Piechocka-Trocha A, Cutrell E, Rosenberg R, Moss KL, Lemay P, O'Leary J, Schaefer T, Verma P, Toth I, Block B, Baker B, Rothchild A, Lian J, Proudfoot J, Alvino DM, Vine S, Addo MM, Allen TM, Altfeld M, Henn MR, Le Gall S, Streeck H, Haas DW, Kuritzkes DR, Robbins GK, Shafer RW, Gulick RM, Shikuma CM, Haubrich R, Riddler S, Sax PE, Daar ES, Ribaudo HJ, Agan B, Agarwal S, Ahern RL, Allen BL, Altidor S, Altschuler EL, Ambardar S, Anastos K, Anderson B, Anderson V, Andrady U, Antoniskis D, Bangsberg D, Barbaro D, Barrie W, Bartczak J, Barton S, Basden P, Basgoz N, Bazner S, Bellos NC, Benson AM, Berger J, Bernard NF, Bernard AM, Birch C, Bodner SJ, Bolan RK, Boudreaux ET, Bradley M, Braun JF, Brndjar JE, Brown SJ, Brown K, Brown ST, Burack J, Bush LM, Cafaro V, Campbell O, Campbell J, Carlson RH, Carmichael JK, Casey KK, Cavacuiti C, Celestin G, Chambers ST, Chez N, Chirch LM, Cimoch PJ, Cohen D, Cohn LE, Conway B, Cooper DA, Cornelson B, Cox DT, Cristofano MV, Cuchural G, Czartoski JL, Dahman JM, Daly JS, Davis BT, Davis K, Davod SM, DeJesus E, Dietz CA, Dunham E, Dunn ME, Ellerin TB, Eron JJ, Fangman JJ, Farel CE, Ferlazzo H, Fidler S, Fleenor-Ford A, Frankel R, Freedberg KA, French NK, Fuchs JD, Fuller JD, Gaberman J, Gallant JE, Gandhi RT, Garcia E, Garmon D, Gathe JC, Gaultier CR, Gebre W, Gilman FD, Gilson I, Goepfert PA, Gottlieb MS, Goulston C, Groger RK, Gurley TD, Haber S, Hardwicke R, Hardy WD, Harrigan PR, Hawkins TN, Heath S, Hecht FM, Henry WK, Hladek M, Hoffman RP, Horton JM, Hsu RK, Huhn GD, Hunt P, Hupert MJ, Illeman ML, Jaeger H, Jellinger RM, John M, Johnson JA, Johnson KL, Johnson H, Johnson K, Joly J, Jordan WC, Kauffman CA, Khanlou H, Killian RK, Kim AY, Kim DD, Kinder CA, Kirchner JT, Kogelman L, Kojic EM, Korthuis PT, Kurisu W, Kwon DS, LaMar M, Lampiris H, Lanzafame M, Lederman MM, Lee DM, Lee JM, Lee MJ, Lee ET, Lemoine J, Levy JA, Llibre JM, Liguori MA, Little SJ, Liu AY, Lopez AJ, Loutfy MR, Loy D, Mohammed DY, Man A, Mansour MK, Marconi VC, Markowitz M, Marques R, Martin JN, Martin HL, Mayer KH, McElrath MJ, McGhee TA, McGovern BH, McGowan K, McIntyre D, Mcleod GX, Menezes P, Mesa G, Metroka CE, Meyer-Olson D, Miller AO, Montgomery K, Mounzer KC, Nagami EH, Nagin I, Nahass RG, Nelson MO, Nielsen C, Norene DL, O'Connor DH, Ojikutu BO, Okulicz J, Oladehin OO, Oldfield EC, Olender SA, Ostrowski M, Owen WF, Pae E, Parsonnet J, Pavlatos AM, Perlmutter AM, Pierce MN, Pincus JM, Pisani L, Price LJ, Proia L, Prokesch RC, Pujet HC, Ramgopal M, Rathod A, Rausch M, Ravishankar J, Rhame FS, Richards CS, Richman DD, Rodes B, Rodriguez M, Rose RC, Rosenberg ES, Rosenthal D, Ross PE, Rubin DS, Rumbaugh E, Saenz L, Salvaggio MR, Sanchez WC, Sanjana VM, Santiago S, Schmidt W, Schuitemaker H, Sestak PM, Shalit P, Shay W, Shirvani VN, Silebi VI, Sizemore JM, Skolnik PR, Sokol-Anderson M, Sosman JM, Stabile P, Stapleton JT, Starrett S, Stein F, Stellbrink HJ, Sterman FL, Stone VE, Stone DR, Tambussi G, Taplitz RA, Tedaldi EM, Telenti A, Theisen W, Torres R, Tosiello L, Tremblay C, Tribble MA, Trinh PD, Tsao A, Ueda P, Vaccaro A, Valadas E, Vanig TJ, Vecino I, Vega VM, Veikley W, Wade BH, Walworth C, Wanidworanun C, Ward DJ, Warner DA, Weber RD, Webster D, Weis S, Wheeler DA, White DJ, Wilkins E, Winston A, Wlodaver CG, van't Wout A, Wright DP, Yang OO, Yurdin DL, Zabukovic BW, Zachary KC, Zeeman B, Zhao M. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science. 2010 Dec 10; 330(6010):1551-7. PMID: 21051598.
    Citations: 466     Fields:    Translation:HumansCells
  68. Hammer SM, Ribaudo H, Bassett R, Mellors JW, Demeter LM, Coombs RW, Currier J, Morse GD, Gerber JG, Martinez AI, Spreen W, Fischl MA, Squires KE. A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen. HIV Clin Trials. 2010 Nov-Dec; 11(6):312-24. PMID: 21239359.
    Citations: 8     Fields:    Translation:HumansCells
  69. Ribaudo HJ, Liu H, Schwab M, Schaeffeler E, Eichelbaum M, Motsinger-Reif AA, Ritchie MD, Zanger UM, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford D, Haas DW. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J Infect Dis. 2010 Sep 01; 202(5):717-22. PMID: 20662624.
    Citations: 61     Fields:    Translation:Humans
  70. Henrich TJ, Ribaudo HJ, Kuritzkes DR. Instantaneous inhibitory potential is similar to inhibitory quotient at predicting HIV-1 response to antiretroviral therapy. Clin Infect Dis. 2010 Jul 01; 51(1):93-8. PMID: 20504163.
    Citations: 6     Fields:    Translation:HumansCells
  71. Paredes R, Lalama CM, Ribaudo HJ, Schackman BR, Shikuma C, Giguel F, Meyer WA, Johnson VA, Fiscus SA, D'Aquila RT, Gulick RM, Kuritzkes DR. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis. 2010 Mar; 201(5):662-71. PMID: 20102271.
    Citations: 66     Fields:    Translation:HumansCells
  72. Schouten JT, Krambrink A, Ribaudo HJ, Kmack A, Webb N, Shikuma C, Kuritzkes DR, Gulick RM. Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095. Clin Infect Dis. 2010 Mar 01; 50(5):787-91. PMID: 20121419.
    Citations: 10     Fields:    Translation:Humans
  73. Rowley CF, Boutwell CL, Lee EJ, MacLeod IJ, Ribaudo HJ, Essex M, Lockman S. Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance. AIDS Res Hum Retroviruses. 2010 Mar; 26(3):293-300. PMID: 20334564.
    Citations: 15     Fields:    Translation:HumansCells
  74. Aberg JA, Ribaudo H. Cardiac risk: not so simple. J Infect Dis. 2010 Feb 01; 201(3):315-7. PMID: 20039805.
    Citations: 5     Fields:    Translation:Humans
  75. Clifford DB, Evans S, Yang Y, Acosta EP, Ribaudo H, Gulick RM. Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). HIV Clin Trials. 2009 Nov-Dec; 10(6):343-55. PMID: 20133265.
    Citations: 19     Fields:    Translation:HumansCellsCTClinical Trials
  76. Ribaudo HJ, Kuritzkes DR, Lalama CM, Schouten JT, Schackman BR, Acosta EP, Gulick RM. Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts. J Infect Dis. 2008 Apr 01; 197(7):1006-10. PMID: 18419537.
    Citations: 8     Fields:    Translation:Humans
  77. Kuritzkes DR, Lalama CM, Ribaudo HJ, Marcial M, Meyer WA, Shikuma C, Johnson VA, Fiscus SA, D'Aquila RT, Schackman BR, Acosta EP, Gulick RM. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis. 2008 Mar 15; 197(6):867-70. PMID: 18269317.
    Citations: 52     Fields:    Translation:HumansCells
  78. Schackman BR, Ribaudo HJ, Krambrink A, Hughes V, Kuritzkes DR, Gulick RM. Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095. J Acquir Immune Defic Syndr. 2007 Dec 15; 46(5):547-54. PMID: 18193496.
    Citations: 29     Fields:    Translation:Humans
  79. Ribaudo HJ, Kuritzkes DR, Gulick RM. A comparison of three initial antiretroviral AIDS regimens. N Engl J Med. 2007 Sep 06; 357(10):1056-7. PMID: 17804858.
    Citations: 2     Fields:    Translation:HumansCells
  80. Ribaudo HJ. Cost-effectiveness evaluation to inform clinical trial design. Clin Infect Dis. 2007 Oct 15; 45(8):1071-3. PMID: 17879927.
    Citations:    Fields:    Translation:Humans
  81. Gulick RM, Lalama CM, Ribaudo HJ, Shikuma CM, Schackman BR, Schouten J, Squires KE, Koletar SL, Pilcher CD, Reichman RC, Klingman KL, Kuritzkes DR. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression. AIDS. 2007 Apr 23; 21(7):813-23. PMID: 17415036.
    Citations: 5     Fields:    Translation:HumansCells
  82. Shikuma CM, Yang Y, Glesby MJ, Meyer WA, Tashima KT, Ribaudo HJ, Webb N, Bastow B, Kuritzkes DR, Gulick RM. Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095). J Acquir Immune Defic Syndr. 2007 Apr 15; 44(5):540-50. PMID: 17245230.
    Citations: 20     Fields:    Translation:HumansCells
  83. Kuritzkes DR, Ribaudo HJ, Squires KE, Koletar SL, Santana J, Riddler SA, Reichman R, Shikuma C, Meyer WA, Klingman KL, Gulick RM. Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s. J Infect Dis. 2007 Apr 15; 195(8):1169-76. PMID: 17357053.
    Citations: 20     Fields:    Translation:HumansCells
  84. Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA, Acosta EP, Schouten J, Squires KE, Pilcher CD, Murphy RL, Koletar SL, Carlson M, Reichman RC, Bastow B, Klingman KL, Kuritzkes DR. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA. 2006 Aug 16; 296(7):769-81. PMID: 16905783.
    Citations: 76     Fields:    Translation:HumansCells
  85. Gripshover BM, Ribaudo H, Santana J, Gerber JG, Campbell TB, Hogg E, Jarocki B, Hammer SM, Kuritzkes DR. Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). Antivir Ther. 2006; 11(5):619-23. PMID: 16964830.
    Citations: 5     Fields:    Translation:HumansCells
  86. Ribaudo HJ, Kuritzkes DR, Schackman BR, Acosta EP, Shikuma CM, Gulick RM. Design issues in initial HIV-treatment trials: focus on ACTG A5095. Antivir Ther. 2006; 11(6):751-60. PMID: 17310819.
    Citations: 6     Fields:    Translation:HumansCells
  87. Ribaudo HJ, Haas DW, Tierney C, Kim RB, Wilkinson GR, Gulick RM, Clifford DB, Marzolini C, Fletcher CV, Tashima KT, Kuritzkes DR, Acosta EP. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis. 2006 Feb 01; 42(3):401-7. PMID: 16392089.
    Citations: 55     Fields:    Translation:Humans
  88. Clifford DB, Evans S, Yang Y, Acosta EP, Goodkin K, Tashima K, Simpson D, Dorfman D, Ribaudo H, Gulick RM. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med. 2005 Nov 15; 143(10):714-21. PMID: 16287792.
    Citations: 70     Fields:    Translation:Humans
  89. Collier AC, Ribaudo H, Mukherjee AL, Feinberg J, Fischl MA, Chesney M. A randomized study of serial telephone call support to increase adherence and thereby improve virologic outcome in persons initiating antiretroviral therapy. J Infect Dis. 2005 Oct 15; 192(8):1398-406. PMID: 16170757.
    Citations: 26     Fields:    Translation:HumansCells
  90. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgan T, Marzolini C, Acosta EP. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004 Dec 03; 18(18):2391-400. PMID: 15622315.
    Citations: 180     Fields:    Translation:HumansCTClinical Trials
  91. Demeter LM, Ribaudo HJ, Erice A, Eshleman SH, Hammer SM, Hellmann NS, Fischl MA. HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388. Clin Infect Dis. 2004 Aug 15; 39(4):552-8. PMID: 15356820.
    Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
  92. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA, Acosta EP, Schackman BR, Pilcher CD, Murphy RL, Maher WE, Witt MD, Reichman RC, Snyder S, Klingman KL, Kuritzkes DR. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004 Apr 29; 350(18):1850-61. PMID: 15115831.
    Citations: 130     Fields:    Translation:HumansCellsCTClinical Trials
  93. DiCenzo R, Forrest A, Fischl MA, Collier A, Feinberg J, Ribaudo H, DiFrancecso R, Morse GD. Pharmacokinetics of indinavir and nelfinavir in treatment-naive, human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother. 2004 Mar; 48(3):918-23. PMID: 14982784.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  94. Fischl MA, Ribaudo HJ, Collier AC, Erice A, Giuliano M, Dehlinger M, Eron JJ, Saag MS, Hammer SM, Vella S, Morse GD, Feinberg JE, Demeter LM, Eshleman SH. A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. J Infect Dis. 2003 Sep 01; 188(5):625-34. PMID: 12934177.
    Citations: 29     Fields:    Translation:HumansCellsCTClinical Trials
  95. Ribaudo HJ, Thompson SG. The analysis of repeated multivariate binary quality of life data: a hierarchical model approach. Stat Methods Med Res. 2002 Feb; 11(1):69-83. PMID: 11923995.
    Citations: 2     Fields:    Translation:Humans
  96. Ribaudo HJ, Thompson SG, Allen-Mersh TG. A joint analysis of quality of life and survival using a random effect selection model. Stat Med. 2000 Dec 15; 19(23):3237-50. PMID: 11113957.
    Citations: 7     Fields:    Translation:Humans
  97. Gilbert PB, Ribaudo HJ, Greenberg L, Yu G, Bosch RJ, Tierney C, Kuritzkes DR. Considerations in choosing a primary endpoint that measures durability of virological suppression in an antiretroviral trial. AIDS. 2000 Sep 08; 14(13):1961-72. PMID: 10997401.
    Citations: 2     Fields:    Translation:HumansCells
  98. Kalkanis SN, Quiñones-Hinojosa A, Buzney E, Ribaudo HJ, Black PM. Quality of life following surgery for intracranial meningiomas at Brigham and Women's Hospital: a study of 164 patients using a modification of the functional assessment of cancer therapy-brain questionnaire. J Neurooncol. 2000 Jul; 48(3):233-41. PMID: 11100821.
    Citations: 14     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: SPH faculty should contact Faculty Affairs at facultyaffairshsph.harvard.edu).
Ribaudo's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (292)
Explore
_
Co-Authors (56)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH/NCATS Clinical and Translational Science Award (CTSA) program, grant number UL1TR001102, and through institutional support from Harvard University, Harvard Medical School, Harvard T.H. Chan School of Public Health, Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Massachusetts General Hospital and the Dana Farber Cancer Institute.